X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24379) 24379
Book Review (3880) 3880
Publication (2121) 2121
Conference Proceeding (305) 305
Book Chapter (111) 111
Dissertation (27) 27
Magazine Article (17) 17
Web Resource (10) 10
Newspaper Article (4) 4
Paper (4) 4
Trade Publication Article (3) 3
Book / eBook (2) 2
Data Set (2) 2
Presentation (2) 2
Reference (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (20520) 20520
index medicus (17178) 17178
humans (16264) 16264
female (9577) 9577
oncology (8330) 8330
male (8171) 8171
middle aged (6887) 6887
aged (6476) 6476
ophthalmology (6130) 6130
chemotherapy (4843) 4843
angiogenesis inhibitors - therapeutic use (4732) 4732
cancer (4597) 4597
adult (4500) 4500
treatment outcome (4403) 4403
antibodies, monoclonal, humanized (4123) 4123
endothelial growth-factor (4056) 4056
vascular endothelial growth factor a - antagonists & inhibitors (3924) 3924
vascular endothelial growth factor (3824) 3824
angiogenesis (3452) 3452
antineoplastic combined chemotherapy protocols - therapeutic use (3408) 3408
ranibizumab (3015) 3015
care and treatment (2943) 2943
aged, 80 and over (2937) 2937
angiogenesis inhibitors - administration & dosage (2924) 2924
therapy (2739) 2739
retrospective studies (2607) 2607
intravitreal injections (2519) 2519
animals (2488) 2488
antibodies, monoclonal - therapeutic use (2423) 2423
macular degeneration (2421) 2421
metastasis (2180) 2180
antibodies, monoclonal - administration & dosage (2093) 2093
colorectal cancer (2082) 2082
medicine & public health (2059) 2059
antibodies, monoclonal, humanized - administration & dosage (2037) 2037
antibodies, monoclonal, humanized - therapeutic use (2005) 2005
survival (1927) 1927
vegf (1923) 1923
research (1910) 1910
antineoplastic agents - therapeutic use (1802) 1802
follow-up studies (1781) 1781
trial (1774) 1774
colorectal neoplasms - drug therapy (1763) 1763
drug therapy (1742) 1742
surgery (1733) 1733
tomography, optical coherence (1723) 1723
disease-free survival (1680) 1680
pharmacology & pharmacy (1649) 1649
analysis (1647) 1647
prognosis (1643) 1643
angiogenesis inhibitors - adverse effects (1635) 1635
eye diseases (1607) 1607
angiogenesis inhibitors (1582) 1582
tumors (1549) 1549
fluorescein angiography (1520) 1520
intravitreal bevacizumab (1503) 1503
patients (1467) 1467
clinical trials (1435) 1435
colorectal neoplasms - pathology (1380) 1380
visual acuity (1358) 1358
prospective studies (1341) 1341
expression (1298) 1298
bevacizumab - administration & dosage (1286) 1286
genetic structures (1271) 1271
antineoplastic agents (1259) 1259
antineoplastic combined chemotherapy protocols - adverse effects (1239) 1239
fluorouracil (1225) 1225
combination (1222) 1222
cetuximab (1217) 1217
neovascularization (1206) 1206
antimitotic agents (1200) 1200
health aspects (1196) 1196
bevacizumab - therapeutic use (1195) 1195
visual acuity - physiology (1189) 1189
mice (1185) 1185
hematology, oncology and palliative medicine (1177) 1177
oxaliplatin (1163) 1163
avastin (1158) 1158
paclitaxel (1146) 1146
abridged index medicus (1138) 1138
lung neoplasms - drug therapy (1138) 1138
antibodies, monoclonal - adverse effects (1107) 1107
1st-line treatment (1098) 1098
phase-ii trial (1098) 1098
phase-iii trial (1067) 1067
neoplasm staging (1063) 1063
efficacy (1058) 1058
risk factors (1057) 1057
cancer therapies (1045) 1045
irinotecan (1045) 1045
neoplasm metastasis (1043) 1043
leucovorin (1042) 1042
injection (1039) 1039
sense organs (1032) 1032
diabetic retinopathy (1019) 1019
article (1017) 1017
glioblastoma (1015) 1015
vascular endothelial growth factor a - metabolism (1009) 1009
choroidal neovascularization - drug therapy (998) 998
combined modality therapy (996) 996
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22382) 22382
German (551) 551
French (520) 520
Japanese (376) 376
Korean (279) 279
Spanish (194) 194
Chinese (83) 83
Turkish (54) 54
Russian (52) 52
Czech (49) 49
Polish (48) 48
Hungarian (36) 36
Portuguese (34) 34
Italian (19) 19
Romanian (13) 13
Dutch (8) 8
Slovenian (7) 7
Croatian (5) 5
Finnish (5) 5
Slovak (4) 4
Swedish (4) 4
Hebrew (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Indonesian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


WHO Drug Information, ISSN 1010-9609, 07/2017, Volume 31, Issue 3, pp. 429 - 429
Avastin® Approval: FDA Use: Treatment of adult patients with certain colorectal, lung, brain, kidney and cervical cancers. Like Avastin®, Mvasi® caries a Boxed... 
Bevacizumab
Journal Article
European Journal of Cancer, ISSN 0959-8049, 08/2019, Volume 117, pp. 131 - 132
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Methylation | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Bioindicators | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2018, Volume 24, Issue 17, pp. 4066 - 4071
The FDA approved niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial... 
TRIAL | ONCOLOGY | BEVACIZUMAB | BREAST
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 77, pp. 13 - 20
Abstract Purpose The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding and thromboembolism. To date, there is no biomarker... 
Hematology, Oncology and Palliative Medicine | Hypertension | Single-nucleotide polymorphism | Bevacizumab-associated toxicity | FOLFIRI/bevacizumab | Autophagy | Colorectal cancer | APOPTOSIS | INHIBITION | ONCOLOGY | SENESCENCE | STRESS | PLUS BEVACIZUMAB | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Middle Aged | Genotype | Male | Neoplasm Metastasis | Protein-Tyrosine Kinases - genetics | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Hypertension - chemically induced | Polymorphism, Single Nucleotide - genetics | Adult | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Autophagy - genetics | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Genetic aspects | Metastasis | Single nucleotide polymorphisms | Thromboembolism | Vascular endothelial growth factor | Medicine, Preventive | Preventive health services | Measurement | Endothelial growth factors | Blood pressure | Toxicity | Genes | Colorectal carcinoma | Clinical trials | Patients | Two phase | Bleeding | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Alleles | Phagocytosis | Genotypes | Polymorphism | Proteinuria | Cancer | Index Medicus
Journal Article
by Eadie, JA and Ip, MS
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, ISSN 0275-004X, 02/2016, Volume 36, Issue 2, pp. E10 - E12
Journal Article
Ophthalmology, ISSN 0161-6420, 04/2019, Volume 126, Issue 4, pp. 639 - 641
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2016, Volume 11, Issue 1, pp. e0148019 - e0148019
Journal Article
OPHTHALMOLOGY, ISSN 0161-6420, 12/2018, Volume 125, Issue 12, pp. 1967 - 1968
Journal Article
JAMA, ISSN 0098-7484, 05/2017, Volume 317, Issue 20, pp. 2072 - 2087
Journal Article
Ophthalmology, ISSN 0161-6420, 2016, Volume 124, Issue 3, pp. 408 - 409
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, pp. e0134308 - e0134308
Anti-vascular endothelial growth factor (VEGF) agents are the mainstay treatment for various angiogenesis-related retinal diseases. Currently, bevacizumab, a... 
ENERGY | ANGIOGENESIS | PHARMACOKINETICS | SAFETY | MULTIDISCIPLINARY SCIENCES | RETINOPATHY | BEVACIZUMAB AVASTIN | NEOVASCULARIZATION | ENDOTHELIAL GROWTH-FACTOR | ADIPOSE-TISSUE | Bevacizumab - pharmacology | Bevacizumab - administration & dosage | Enzyme-Linked Immunosorbent Assay | Intravitreal Injections | Mice, Inbred C57BL | Autoantibodies - administration & dosage | Vascular Endothelial Growth Factor A - immunology | Autoantibodies - pharmacology | Autoantibodies - immunology | Adipose Tissue, Brown - chemistry | Animals | Fluorescent Antibody Technique | Animals, Newborn - anatomy & histology | Autoantibodies - analysis | Adipose Tissue, Brown - drug effects | Mice | Adipose Tissue, Brown - blood supply | Retinal Neovascularization - drug therapy | Real-Time Polymerase Chain Reaction | Vascular Endothelial Growth Factor A - physiology | Bevacizumab - immunology | Bevacizumab - analysis | Adipose tissues | Viral antibodies | Infants (Premature) | Body weight | Antibodies | Mitochondrial DNA | Vascular endothelial growth factor | Neonates | Diabetic retinopathy | Retinopathy | Adipose tissue | Laboratories | Homeostasis | Retina | Infants | Bevacizumab | Proteins | Angiogenesis | Mitochondria | Newborn babies | Rodents | Adipose tissue (brown) | Recombinant | Complications | Research & development--R&D | Medical treatment | Injection | Gene expression | Medicine | Hypoxia | Diabetes | Index Medicus | Research & development | R&D
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2016, Volume 27, Issue 1, pp. 140 - 147
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, ISSN 0721-832X, 07/2019, Volume 257, Issue 7, pp. 1571 - 1571
The IRB number of the published article was A-2015-016 (page 1512, 1st paragraph of the method section). 
Medical colleges | Bevacizumab
Journal Article